Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide dose-ranging study in T2DM on metformin
NCT00423501Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Primary completion
- Nov 2007
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of taspoglutide in type 2 diabetes mellitus (T2DM), sponsored by Roche. Primary endpoint: Absolute change from baseline in HbA1c at Week 8. Started Feb 2007; status: completed.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00423501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423501.